III.J.08. Treatments to Prevent Secondary Damage After Hemorrhage or Major Injuries. Transition to development or operational use the materiel and information required to reduce complications and death resulting from massive blood loss or major injuries, including measures to minimize irreversible damage during potentially prolonged evacuation. By FY96, transition a pharmacologic intervention capable of blocking the early steps in development of brain and/or spinal cord injury that occur secondarily to trauma, reducing irreversible damage by at least 20 percent. By FY98, transition a pharmacologic intervention that will reduce ischemia/reperfusion injury by 20 percent under conditions in which definitive treatment is delayed by up to 24 hours. By FY00, transition an intervention that will prevent or reduce by 35 percent trauma induced immunosuppression and related sepsis. By FY04, transition an intervention that interrupts the immunological and biochemical events leading to cell death and organ failure after hemorrhage or major trauma allowing a reduction in deaths by 20 percent under conditions where treatment is delayed by up to 24 hours. By FY04, transition an intervention for far-forward use which reduces the metabolic demands of casualties by 50 percent, providing protection against shock.
Supports: Army Modernization Plan, Medical Annex OProject, Sustain, and Protect the ForceFar Forward Surgical Care. Products include a therapeutic antibody for the treatment of sepsis and a recombinant delta opioid (DADLE) for use in the delay or prevention of multiple organ failure. Food and Drug Administration regulatory requirements.
|STO Manager:||TSO:||TRADOC POC:|
|LTC D. Calcagni||MAJ Mark Seymour||Herbert Russakoff|
|MRMC||SARD-TM||CSS Battle Lab|